Taking advantage of technology that can analyze tissue samples and measure the activity of thousands of genes at once, scientists at Wake Forest Baptist Medical Center are on a mission to better understand and treat interstitial cystitis (IC), a painful and difficult-to-diagnose bladder condition.
"We are looking for molecular biomarkers for IC, which basically means we are comparing bladder biopsy tissue from patients with suspected interstitial cystitis to patients without the disease. The goal is to identify factors that will lead to a more definitive diagnosis, and then use this information to tailor treatments to the patient," said senior author Stephen J. Walker, Ph.D., associate professor at Wake Forest Baptist's Institute for Regenerative Medicine.
The team's initial work, published online ahead of print in the Journal of Urology, found that tissue from IC patients with low bladder capacity had a significantly different gene expression profile than both IC patients with normal bladder capacity and study participants without IC. The findings suggest there may be a sub-type of IC.
"This is the first study to document functional genomic variation based solely on bladder capacity," said Robert J. Evans, M.D., a co-author and IC specialist in Wake Forest Baptist Urology. "Interstitial cystitis is notoriously difficult to diagnose. In fact, one report found that it takes the average patient eight years and seeing five doctors to be correctly diagnosed. The identification of biomarkers to improve diagnosis or treatment would be a significant breakthrough for patients and physicians."
IC, also known as bladder pain syndrome, is a condition in which the bladder lining is tender and easily irritated. Symptoms can include severe pelvic pain, urinary urgency and frequency and painful sexual intercourse. IC is often misdiagnosed as other conditions such as endometriosis, kidney stones or chronic urinary tract infections. The condition affects an estimated three to eight million women and one to four million men in the United States.
For the study, researchers analyzed bladder biopsies from 13 patients diagnosed with IC and three patients without the condition. The biopsies were sorted into three groups: low bladder capacity (less than 13 fluid ounces as tested under anesthesia); bladder capacity above 13 ounces; and non-IC patients. Using microarray analysis, which allows gene expression profiling on a "whole genome" scale, the researchers looked for similarities and differences in gene expression between groups. The analysis tells researchers which genes are turned "on" and which are turned "off."
The results showed a highly significant difference between low capacity patients and both the normal capacity and control patients. The low capacity patients had genes related to inflammation and immune signaling turned "on." The results may reflect a fundamental difference in disease processes.
"These gene expression differences may explain why clinical trials for IC are so variable in effectiveness and have a large number of non-responders," said Evans. "There may be subtypes of the disease that respond best to particular treatments."
Based on these early results, the team is conducting further research with the aim of identifying and validating a biomarker to aid in diagnosis and treatment of IC.
"Diseases are rarely seen as single entities anymore," said Walker. "Patients demonstrating a specific disease subtype may respond more quickly and or more favorably to treatments that target that specific subtype. Having the ability to identify the right treatment for the right patient is the ultimate goal."
This pilot research was supported by funds from the Department of Urology. Because of the promise of the data, the Interstitial Cystitis Association has awarded funding for further research.
Co-researchers were: Marc Colaco, M.D., David S. Koslov, M.D., Tristan Keys, M.D., Gopal H. Badlani, M.D., and Karl-Erik Andersson, M.D., Ph.D., all with Wake Forest Baptist.
Media Contacts: Karen Richardson, email@example.com, (336) 716-4453) or Main Number (336) 716-4587.
Wake Forest Baptist Medical Center is a nationally recognized academic medical center in Winston-Salem, N.C., with an integrated enterprise including educational and research facilities, hospitals, clinics, diagnostic centers and other primary and specialty care facilities serving 24 counties in northwest North Carolina and southwest Virginia. Its divisions are Wake Forest Baptist Health, a regional clinical system with close to 175 locations, 900 physicians and 1,000 acute care beds; Wake Forest School of Medicine, an established leader in medical education and research; and Wake Forest Innovations, which promotes the commercialization of research discoveries and operates Wake Forest Innovation Quarter, an urban research and business park specializing in biotechnology, materials science and information technology. Wake Forest Baptist clinical, research and educational programs are annually ranked among the best in the country by U.S. News & World Report.
Karen Richardson | Eurek Alert!
Another piece of Ebola virus puzzle identified
17.01.2019 | Texas Biomedical Research Institute
New scale for electronegativity rewrites the chemistry textbook
17.01.2019 | Chalmers University of Technology
World first experiments on sensor that may revolutionise everything from medical devices to unmanned vehicles
The new sensor - capable of detecting vibrations of living cells - may revolutionise everything from medical devices to unmanned vehicles.
Dead and alive at the same time? Researchers at the Max Planck Institute of Quantum Optics have implemented Erwin Schrödinger’s paradoxical gedanken experiment employing an entangled atom-light state.
In 1935 Erwin Schrödinger formulated a thought experiment designed to capture the paradoxical nature of quantum physics. The crucial element of this gedanken...
Cellulose obtained from wood has amazing material properties. Empa researchers are now equipping the biodegradable material with additional functionalities to produce implants for cartilage diseases using 3D printing.
It all starts with an ear. Empa researcher Michael Hausmann removes the object shaped like a human ear from the 3D printer and explains:
The phenomenon of so-called superlubricity is known, but so far the explanation at the atomic level has been missing: for example, how does extremely low friction occur in bearings? Researchers from the Fraunhofer Institutes IWM and IWS jointly deciphered a universal mechanism of superlubricity for certain diamond-like carbon layers in combination with organic lubricants. Based on this knowledge, it is now possible to formulate design rules for supra lubricating layer-lubricant combinations. The results are presented in an article in Nature Communications, volume 10.
One of the most important prerequisites for sustainable and environmentally friendly mobility is minimizing friction. Research and industry have been dedicated...
Just in time for Christmas, a Mars-analogue mission in Morocco, coordinated by the Robotics Innovation Center of the German Research Center for Artificial Intelligence (DFKI) as part of the SRC project FACILITATORS, has been successfully completed. SRC, the Strategic Research Cluster on Space Robotics Technologies, is a program of the European Union to support research and development in space technologies. From mid-November to mid-December 2018, a team of more than 30 scientists from 11 countries tested technologies for future exploration of Mars and Moon in the desert of the Maghreb state.
Close to the border with Algeria, the Erfoud region in Morocco – known to tourists for its impressive sand dunes – offered ideal conditions for the four-week...
16.01.2019 | Event News
14.01.2019 | Event News
12.12.2018 | Event News
17.01.2019 | Physics and Astronomy
17.01.2019 | Materials Sciences
17.01.2019 | Information Technology